Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1314 in Active Psoriatic Arthritis
NCT06640257Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing SHR-1314 injection with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20% Improvement at 24 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
vunakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06640257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640257.